Similar articles

Abstract: Patients with diabetic peripheral neuropathy experience debilitating pain that significantly affects their quality of life (Abbott et al., 2011), by causing sleeping disorders, anxiety, and depression (Dermanovic Dobrota et al., 2014). The primary clinical manifestation of painful diabetic neuropathy (PDN) is mechanical hypersensitivity, also known as mechanical allodynia (MA) (Callaghan et al., 2012). MA’s underlying mechanism remains poorly understood, and so far, based on symptomatic treatment, it has no effective therapy (Moore et al., 2014).

CX3CL1受体参与1型糖尿病机械痛的形成

[1]Abbott CA, Malik RA, van Ross ERE, et al., 2011. Prevalence and characteristics of painful diabetic neuropathy in a large community-based diabetic population in the U.K. Diabetes Care, 34(10):2220-2224.

[2]Badr G, Badr BM, Mahmoud MH, et al., 2012. Treatment of diabetic mice with undenatured whey protein accelerates the wound healing process by enhancing the expression of MIP-1α, MIP-2, KC, CX3CL1 and TGF-β in wounded tissue. BMC Immunol, 13:32.

[3]Callaghan BC, Cheng HT, Stables CL, et al., 2012. Diabetic neuropathy: clinical manifestations and current treatments. Lancet Neurol, 11(6):521-534.

[4]Cameron NE, Eaton SEM, Cotter MA, et al., 2001. Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia, 44(11):1973-1988.

[5]Cao H, Zhao YQ, 2008. Spinal glial activation contributes to pathological pain states. Neurosci Biobehav Rev, 32(5):972-983.

[6]Clark AK, Yip PK, Malcangio M, 2009. The liberation of fractalkine in the dorsal horn requires microglial cathepsin S. J Neurosci, 29(21):6945-6954.

[7]Dansereau MA, Gosselin RD, Pohl M, et al., 2008. Spinal CCL2 pronociceptive action is no longer effective in CCR2 receptor antagonist-treated rats. J Neurochem, 106(2):757-769.

[8]Dermanovic Dobrota V, Hrabac P, Skegro D, et al., 2014. The impact of neuropathic pain and other comorbidities on the quality of life in patients with diabetes. Health Qual Life Outcomes, 12:171.

[9]Guo XX, Wang Y, Wang K, et al., 2018. Stability of a type 2 diabetes rat model induced by high-fat diet feeding with low-dose streptozotocin injection. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 19(7):559-569.

[10]Inoguchi T, Li P, Umeda F, et al., 2000. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes, 49(11):1939-1945.

[11]Ji RR, Chamessian A, Zhang YQ, 2016. Pain regulation by non-neuronal cells and inflammation. Science, 354(6312):572-577.

[12]Kiyomoto M, Shinoda M, Okada-Ogawa A, et al., 2013. Fractalkine signaling in microglia contributes to ectopic orofacial pain following trapezius muscle inflammation. J Neurosci, 33(18):7667-7680.

[13]Lee YS, Morinaga H, Kim JJ, et al., 2013. The fractalkine/CX3CR1 system regulates β cell function and insulin secretion. Cell, 153(2):413-425.

[14]Lindia JA, McGowan E, Jochnowitz N, et al., 2005. Induction of CX3CL1 expression in astrocytes and CX3CR1 in microglia in the spinal cord of a rat model of neuropathic pain. J Pain, 6(7):434-438.

[15]Mika J, Zychowska M, Popiolek-Barczyk K, et al., 2013. Importance of glial activation in neuropathic pain. Eur J Pharmacol, 716(1-3):106-119.

[16]Milligan E, Zapata V, Schoeniger D, et al., 2005. An initial investigation of spinal mechanisms underlying pain enhancement induced by fractalkine, a neuronally released chemokine. Eur J Neurosci, 22(11):2775-2782.

[17]Moore RA, Wiffen PJ, Derry S, et al., 2014. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev, (4):CD007938.

[18]Nishikawa T, Edelstein D, Du XL, et al., 2000. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature, 404(6779):787-790.

[19]Oyama T, Miyasita Y, Watanabe H, et al., 2006. The role of polyol pathway in high glucose-induced endothelial cell damages. Diabetes Res Clin Pract, 73(3):227-234.

[20]Rajchgot T, Thomas SC, Wang JC, et al., 2019. Neurons and microglia; a sickly-sweet duo in diabetic pain neuropathy. Front Neurosci, 13:25.

[21]Souza GR, Talbot J, Lotufo CM, et al., 2013. Fractalkine mediates inflammatory pain through activation of satellite glial cells. Proc Natl Acad Sci USA, 110(27):11193-11198.

[22]Sugimoto K, Yasujima M, Yagihashi S, 2008. Role of advanced glycation end products in diabetic neuropathy. Curr Pharm Des, 14(10):953-961.

[23]Svensson CI, Fitzsimmons B, Azizi S, et al., 2005. Spinal p38β isoform mediates tissue injury-induced hyperalgesia and spinal sensitization. J Neurochem, 92(6):1508-1520.

[24]Tsuda M, Inoue K, Salter MW, 2005. Neuropathic pain and spinal microglia: a big problem from molecules in ‘small’ glia. Trends Neurosci, 28(2):101-107.

[25]Xu AK, Gong Z, He YZ, et al., 2019. Comprehensive therapeutics targeting the corticospinal tract following spinal cord injury. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 20(3):205-218.

[26]Yao L, Wu YT, Tian GX, et al., 2017. Acrolein scavenger hydralazine prevents streptozotocin-induced painful diabetic neuropathy and spinal neuroinflammation in rats. Anat Rec (Hoboken), 300(10):1858-1864.

[27]Zhang Y, Yan J, Hu R, et al., 2015. Microglia are involved in pruritus induced by DNFB via the CX3CR1/p38 MAPK pathway. Cell Physiol Biochem, 35(3):1023-1033.

[28]Zhao H, Alam A, Chen Q, et al., 2017. The role of microglia in the pathobiology of neuropathic pain development: what do we know? Br J Anaesth, 118(4):504-516.

[29]Zochodne DW, Verge VMK, Cheng C, et al., 2000. Nitric oxide synthase activity and expression in experimental diabetic neuropathy. J Neuropathol Exp Neurol, 59(9):798-807.